ERBB2 and breast cancer: Another HER2-specific humanized monoclonal antibody pertuzumab (PerjetaTM, Genentech Inc.)recognizes a rather distal located extracellular HER2 epitope and became clinically approved in combination with trastuzumab for the treatment of BC patients in the neoadjuvant and adjuvant setting.